Form 13-F position report

GINKGO BIOWORKS HOLDINGS INC C

Reported by MORGAN STANLEY

DNA CUSIP 37611X100 Manager CIK 0000895421

Reported 39,213,029 shares, up 14,233,562 (57.0%) from the prior quarter.

Reported value -7.3%; share count 57.0% vs. the prior quarter.

Added
% of reported 13F value 0.01% This manager · Q2 2022
Shares 39,213,029 Quarter-end amount reported
Reported value $93,329,000 Fair value at quarter end
Consecutive quarters held 4 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 130670000
2021-12-31 120786000
2022-03-31 100667000
2022-06-30 93329000
2022-09-30 169239000
2022-12-31 86332382
2023-03-31 78523756
2023-06-30 89394242
2023-09-30 90079029
2023-12-31 82747165
2024-03-31 56922663
2024-06-30 2005469
2024-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

13 quarters
Quarterly reported position history for GINKGO BIOWORKS HOLDINGS INC C held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Reduced 0 -5,999,010 (-100.0%) 0 $0 2024-11-14
Q2 2024 Reduced 5,999,010 -43,072,251 (-87.8%) < 0.01% $2,005,469 2024-08-14
Q1 2024 Added 49,071,261 +108,442 (0.2%) < 0.01% $56,922,663 2024-05-15
Q4 2023 Reduced 48,962,819 -804,601 (-1.6%) < 0.01% $82,747,165 2024-02-13
Q3 2023 Added 49,767,420 +1,706,002 (3.5%) < 0.01% $90,079,029 2023-11-15
Q2 2023 Reduced 48,061,418 -10,979,001 (-18.6%) < 0.01% $89,394,242 2023-08-14
Q1 2023 Added 59,040,419 +7,956,169 (15.6%) < 0.01% $78,523,756 2023-05-15
Q4 2022 Reduced 51,084,250 -3,159,411 (-5.8%) < 0.01% $86,332,382 2023-02-14
Q3 2022 Added 54,243,661 +15,030,632 (38.3%) 0.02% $169,239,000 2022-11-14
Q2 2022 Added 39,213,029 +14,233,562 (57.0%) 0.01% $93,329,000 2022-08-15
Q1 2022 Added 24,979,467 +10,444,491 (71.9%) 0.01% $100,667,000 2022-05-13
Q4 2021 Added 14,534,976 +3,260,553 (28.9%) 0.01% $120,786,000 2022-02-14
Q3 2021 New 11,274,423 +11,274,423 (0.0%) 0.02% $130,670,000 2021-11-15

Who else reported the position

278 managers reported GINKGO BIOWORKS HOLDINGS INC C for Q2 2022.

Managers reporting GINKGO BIOWORKS HOLDINGS INC C in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BAILLIE GIFFORD & CO Added 205,327,786 +37,575,106 0.5% $488,680,000 4 qtrs
ARK Investment Management LLC Added 87,358,057 +22,824,417 1.59% $269,063,000 4 qtrs
VANGUARD GROUP INC Added 86,735,032 +57,401,650 < 0.01% $206,429,000 3 qtrs
GENERAL ATLANTIC L P Reduced 69,435,733 -21,375,081 2.16% $165,257,000 4 qtrs
Anchorage Capital Group L L C Unchanged 69,158,354 0 16.46% $164,597,000 4 qtrs
MORGAN STANLEY This report Added 39,213,029 +14,233,562 0.01% $93,329,000 4 qtrs
BlackRock Inc Added 32,353,263 +16,399,997 < 0.01% $77,001,000 3 qtrs
VIKING GLOBAL INVESTORS LP Reduced 27,084,126 -23,971,018 0.29% $64,460,000 4 qtrs
Nikko Asset Management Americas Inc Added 21,858,173 +6,937,185 0.65% $52,678,000 4 qtrs
Sumitomo Mitsui Trust Holdings Inc New 21,858,173 +21,858,173 0.04% $52,022,000 4 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
CL A SHS

Voting authority reported

Sole
34,673,054
Shared
43,004
None
4,496,971

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.